Alphamab’s Novel Subcutaneous Anti-HER2 Bispecific ADC JSKN033 Approved for Clinical Studies in Australia

On December 11, 2023 Alphamab Oncology (stock code: 9966.HK) reported that the independently developed global first subcutaneous injection HER2 bispecific antibody-conjugated drug (JSKN033) has received approval from the Australian Bellberry Clinical Research Ethics Committee to conduct clinical studies (JSKN033-101) for the treatment of HER2-expressing advanced or metastatic solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JSKN033-101 is an open-label, muticenter, phase I/II clinical study. The study consists of dose escalation and dose expansion phases: The Phase I dose escalation stage aims to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JSKN033 in patients with advanced or metastatic HER2-expressing solid tumors, determining the maximum tolerated dose (MTD) and/or Phase II recommended dose (RP2D); the Phase II dose expansion stage will evaluate the efficacy and safety of JSKN033 in HER2-expressing gastrointestinal tumors at the RP2D dose.

JSKN033 is a subcutaneous injection compound consisting of JSKN003 and envafolimab, independently developed by Alphamab. JSKN033 is expected to provide effective innovative therapy for patients and doctors through IO and ADC combo and have better safety profile and convenience due to the nature of SubC injectables.

About JSKN033

JSKN033 is the global first subcutaneous injection HER2 bispecific antibody-conjugated drug developed by Alphamab, which is composed of JSKN003 and envafolimab. JSKN003 is a HER2 dual-epitope-targeting antibody-conjugated drug composed of three parts: bispecific antibodies targeting two non-overlapping epitopes of the HER2 extracellular domain, a cleavable linker, and a topoisomerase I inhibitor. Envafolimab is a Fc fusion protein consisting of humanized anti-PD-L1 single domain antibody and human IgG1 Fc fragment, which has been approved by China NMPA as the global first subcutaneously administered PD-L1 inhibitor and marketed in China.

(Press release, Alphamab, DEC 11, 2023, View Source [SID1234657029])